Auxilart to Speak at the 35th Anniversary Conference of the Japan Society of Pharmaceutical Machinery and Engineering (製剤機械技術学会) on October 2025

Auxilart Co., Ltd. (Headquarters: Tokyo, Japan, CEO: Junu Kim) announced that Keisuke (Kay) Okita, Chief Operating Officer, will speak at the 35th Anniversary Conference of Japan Society of Pharmaceutical Machinery and Engineering (製剤機械技術学会) in Tokyo on October 7, 2025. In his presentation, he will showcase model-based process development to promote digitalization of pharmaceutical manufacturing development processes. 

The presentation will explore how the pharmaceutical industry should advance toward digitalized and more sophisticated development processes. It will introduce Auxilart’s initiatives to support model-based process development. Drawing on the knowledge gained through these efforts, the presentation will also outline key considerations for effectively implementing and operating model-based process development within pharmaceutical companies.

Presentation Details: 

• Title: “Introduction and Practice of Model-Based Process Development (モデルベースプロセス開発の導入と実践)” 

• Date and Time: Tuesday, October 7, 2025, 14:25-15:10 JST

About Japan Society of Pharmaceutical Machinery and Engineering (製剤機械技術学会) 

Japan Society of Pharmaceutical Machinery and Engineering (JSPME) is an academic association dedicated to advancing expertise and technology in pharmaceutical manufacturing, integrating both hardware and software aspects. Through its annual meetings, conferences, and training programs, JSPME provides a platform for technical exchange. Today, it brings together over 800 members from diverse fields, including pharmaceuticals, pharmaceutical machinery and measurement, engineering, and academia.

For more information, visit https://seikiken.or.jp/.

About Auxilart

Auxilart Inc. provides advanced digital simulation solutions based on mechanistic models developed at the University of Tokyo, where the technology has been developed over a decade.

Our Mechanistic model-based simulation technology enables high-precision simulations with minimal data, using only 1% of the data typically required by AI-based methods. By replacing extensive physical experiments with digital simulations, we achieve up to 90% reduction in both cost and time while enhancing productivity.

Founded in 2023, Auxilart has already provided its solutions to Boehringer Ingelheim, Daiichi Sankyo and major Japanese pharmaceutical companies.

For more information, visit Auxilart's Website.

Media Contact

Auxilart Co., Ltd.
Established: July 19, 2023
CEO: Junu Kim
Headquarters: 6F, 1-12-4 Ginza, Chuo-ku, Tokyo, Japan

Contact Person: Kay (Keisuke) Okita
Email: information@auxilart.com